International Journal of Antimicrobial Agents
Volume 35, Issue 5 , Pages 497-499 , May 2010

Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin

  • Matthew E. Falagas

      Affiliations

    • Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece
    • Department of Medicine, Tufts University School of Medicine, Boston, MA, USA
    • Department of Medicine, Henry Dunant Hospital, Athens, Greece
    • Corresponding Author InformationCorresponding author. Tel.: +30 694 611 0000; fax: +30 210 683 9605.
    • ,
  • Sofia Maraki

      Affiliations

    • Department of Clinical Bacteriology, University Hospital of Heraklion, Heraklion, Crete, Greece
    • ,
  • Drosos E. Karageorgopoulos

      Affiliations

    • Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece
    • ,
  • Antonia C. Kastoris

      Affiliations

    • Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece
    • ,
  • Anastasios Kapaskelis

      Affiliations

    • Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece
    • Department of Medicine, Henry Dunant Hospital, Athens, Greece
    • ,
  • George Samonis

      Affiliations

    • Department of Medicine, University Hospital of Heraklion, Heraklion, Crete, Greece

Received 14 December 2009 ,Accepted 5 January 2010.

References 

  1. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med. 2004;10(12 Suppl.):S122–S129
  2. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century—a clinical super-challenge. N Engl J Med. 2009;360:439–443
  3. Karageorgopoulos DE, Falagas ME. New antibiotics: optimal use in current clinical practice. Int J Antimicrob Agents. 2009;34(Suppl. 4):S55–S62
  4. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008;46:1069–1077
  5. Reeves DS. Fosfomycin trometamol. J Antimicrob Chemother. 1994;34:853–858
  6. Thomson RB. Specimen collection, transport and processing: bacteriology. In: 9th ed..  Murray P,  Baron EJ,  Jorgensen JH,  Landry ML,  Pfaller MA editor. Manual of clinical microbiology. vol. 1:Washington, DC: American Society for Microbiology; 2007;p. 291–333
  7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement. Document M100-S17. Wayne, PA: CLSI, 2007.
  8. Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs. 2009;18:921–944
  9. Barakett V, Lesage D, Delisle F, Burghoffer B, Richard G, Vergez P, et al. Synergy of cefotaxime and fosfomycin against penicillin-resistant pneumococci. J Antimicrob Chemother. 1993;31:105–109
  10. Georgopapadakou NH, Liu FY. Binding of β-lactam antibiotics to penicillin-binding proteins of Staphylococcus aureus and Streptococcus faecalis: relation to antibacterial activity. Antimicrob Agents Chemother. 1980;18:834–836
  11. Ellington MJ, Livermore DM, Pitt TL, Hall LM, Woodford N. Mutators among CTX-M β-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance. J Antimicrob Chemother. 2006;58:848–852
  12. Nakaminami H, Noguchi N, Nishijima S, Kurokawa I, Sasatsu M. Characterization of the pTZ2162 encoding multidrug efflux gene qacB from Staphylococcus aureus. Plasmid. 2008;60:108–117
  13. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents. 2009;34:506–515
  14. Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008;148:249–257
  15. Careddu P, Borzani M, Scotti L, Varotto F, Garlaschi L, Fontana P. Treatment of lower urinary tract infections in children: single dose fosfomycin trometamol versus pipemidic acid. Chemioterapia. 1987;6:290–294

PII: S0924-8579(10)00053-1

doi: 10.1016/j.ijantimicag.2010.01.010

International Journal of Antimicrobial Agents
Volume 35, Issue 5 , Pages 497-499 , May 2010

Article Tools